GNL3L: A Promising Drug Target / Biomarker (G54552)

Target Name: GNL3L

NCBI ID: G54552

GNL3L

GNL3L: A Promising Drug Target / Biomarker

Gln-3 (Glu-3) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the glial cell lineage, which is a diverse family of proteins that play a critical role in the support and maintenance of neural circuits in the central nervous system (CNS). Gln-3 is one of the proteins that belong to the GnRH (Gonadotropin-Releasing Hormone) family, which is responsible for regulating various physiological processes in the body, including sexual function and reproduction.

The GnRH family of proteins consists of four isoforms: GnRH1, GnRH2, GnRH3, and GnRH4. GnRH1 and GnRH2 are involved in the production of GnRH, which is a hormone that plays a critical role in the regulation of sexual function and reproduction. GnRH2 is the protein that is targeted by the drug fenofibrate, which is used to treat type 2 diabetes. GnRH3 and GnRH4 are not yet targeted by drugs.

Gln-3 functions as a negative regulator of GnRH1, which means that it inhibits the activity of GnRH1 and prevents it from interacting with its receptor, Gq. GnRH1 is a key transcription factor that is involved in the regulation of various physiological processes, including fetal development, stem cell proliferation, and neurogenesis. GnRH1 has been shown to play a critical role in the development and maintenance of the nervous system, as well as in the regulation of reproductive processes.

Gln-3 has been shown to be involved in various physiological processes in the brain, including the regulation of neurogenesis, the establishment of neural circuits, and the regulation of synaptic plasticity. GnRH1 has been shown to play a critical role in the regulation of neurogenesis, as it is involved in the production of neurons and glial cells, which are important for the development and maintenance of neural circuits. GnRH3 has been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Gln-3 has also been shown to play a critical role in the regulation of the immune system, which is responsible for protecting the body against infection and disease. GnRH1 has been shown to play a critical role in the regulation of immune cell function, as it is involved in the production of antibodies and T cells, which are important for immune defense.

Drugs that target GnRH1 or GnRH3 have been shown to be effective in treating various diseases, including type 2 diabetes and certain types of cancer. However, drugs that target GnRH4 have not yet been developed. GnRH4 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family, which is a diverse family of proteins that play a critical role in the regulation of various physiological processes in the body.

GnRH4 has been shown to play a critical role in the regulation of cardiovascular function, as it is involved in the regulation of heart rate and blood pressure. GnRH4 has also been shown to play a critical role in the regulation of the immune system, as it is involved in the regulation of immune cell function.

Gln-3 has been shown to be involved in the regulation of various physiological processes in the body, including neurogenesis, synaptic plasticity, and cardiovascular function. As a result, GnRH4 and GnRH3 may be potential drug targets (or biomarkers) that can be targeted by small molecules or other therapeutic agents.

Conclusion

Gln-3 is a protein that is expressed in various tissues of the body and is involved in the regulation of various physiological processes, including neurogenesis, synaptic plasticity, and cardiovascular function. GnRH1 and GnRH3 are the

Protein Name: G Protein Nucleolar 3 Like

Functions: Stabilizes TERF1 telomeric association by preventing TERF1 recruitment by PML. Stabilizes TERF1 protein by preventing its ubiquitination and hence proteasomal degradation. Does so by interfering with TERF1-binding to FBXO4 E3 ubiquitin-protein ligase. Required for cell proliferation. By stabilizing TRF1 protein during mitosis, promotes metaphase-to-anaphase transition. Stabilizes MDM2 protein by preventing its ubiquitination, and hence proteasomal degradation. By acting on MDM2, may affect TP53 activity. Required for normal processing of ribosomal pre-rRNA. Binds GTP

The "GNL3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNL3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets